NanoPhoria Bioscience

NanoPhoria is a biotechnology company located in Milan, Italy, focusing on the development of multifunctional non-viral drug delivery platforms based on inorganic nanoparticles. The company's mission is to provide revolutionary treatments to improve the quality of life for patients with heart failure. As a branch of the CNR (National Research Council), NanoPhoria receives support and resources from Italy's largest public research institution. They collaborate with Sofinnova Partners to jointly promote the research, development, and commercialization of innovative therapeutic solutions. NanoPhoria’s first product is a preclinical treatment for heart failure, specifically targeting patients with reduced ejection fraction (HFrEF). Heart failure is a chronic syndrome that affects millions of people worldwide. NanoPhoria aims to use its unique drug delivery platform to provide more effective and sustainable treatments, improving patients’ cardiac function and quality of life.